fda compounding semaglutide crackdown october 2025 issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of September 15, 2025: Telehealth company

Body composition analysis revealed lean mass changes comparable to those seen with other obesity treatments

First, most studies have been conducted in male rodents, limiting the generalizability of findings to female subjects and precluding analysis of sex-dependent responses

We didnt need it to be the funniest or most entertaining ad of the night

This complex metabolic and hormonal condition affects multiple body systems and can have lasting implications for your overall health if left unmanaged

It is essential to monitor for adverse events such as hypoglycemic episodes and blood pressure changes when using semaglutide, particularly in individuals with cardiovascular disease or risk factors related to heart attack and stroke

Check with your provider before use